Clinical Trial Update: Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib malate in persistent or recurrent clear cell ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinoma
• Ovarian Clear Cell Adenocarcinoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-21